(E/Z)-Afatinib
Product Sizes
250 mg
£ POA
HY-10261B-250MG
100 mg
£ POA
HY-10261B-100MG
10mM/1mL
£ POA
HY-10261B-10MM
About this Product
- SKU:
- HY-10261B
- Additional Names:
- (E/Z)-BIBW 2992
- CAS Number:
- 439081-18-2
- Extra Details:
- (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR; by irreversibly binding to their ATP binding site to block activation of EGFR; HER2; HER4; and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364); potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1].
- Molecular Weight:
- 485.94
- Purity:
- 99.98
- References:
- [1]Yoshioka T, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018 Apr;109(4):1166-1176.|[2]Wang XK, et al. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 2014 Dec 15;5(23):11971-85.|[3]Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-11.|[4]Wong CH, et al. Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). Am J Cancer Res. 2015 Nov 15;5(12):3588-99.
- Research Area:
- Others; Cancer
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C (Powder; protect from light)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Apoptosis;Autophagy;JAK/STAT Signaling;MAPK/ERK Pathway;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK
